Opinion|Videos|January 14, 2025
Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer
Panelists discuss how the latest NCCN guidelines for targeted therapies and biomarker testing in advanced/metastatic breast cancer highlight the importance of biomarker-driven approaches, with particular emphasis on the need for next-generation sequencing testing in the first-line setting, the implications of HER2-low classification, and how the recent FDA approval of a PI3K inhibitor may impact testing practices and treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please briefly mention the latest NCCN guidelines for targeted therapies and associated biomarker testing.
- How does biomarker testing differ in advanced/metastatic breast cancer from early-stage disease?
- What should be considered when testing in the first line for advanced disease?
- Is there a need for next-generation sequencing testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, microsatellite instability–high/mismatch repair deficiency, high tumor mutational burden)
- Will the recent FDA approval of a PI3K inhibitor affect your testing practice?
- For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
- How has immunohistochemistry (IHC) testing changed with the addition of HER2-low to NCCN guidelines?
- How are you interpreting IHC staining results for HER2-low?
- How are results reported? Are you given a percentage of staining, or are you given the category of HER2-low?
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5